SequelSEC

CalciMedica, Inc. CALC

Pharmaceutical Preparations · CIK 0001534133 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$23.12M
Fiscal year ended 2025-12-31
Free cash flow
-$21.21M
Fiscal year ended 2025-12-31

CalciMedica, Inc. (CALC) reported net income of -$29.56M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from CalciMedica, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CalciMedica, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$23.12M-$24.20M-$38.08M-$14.19M-$35.95M-$29.83M-$37.50M
Net income-$29.56M-$13.70M-$34.36M-$7.82M-$35.82M-$27.53M-$37.04M
Research & development$15.23M$14.48M$15.86M$8.35M$18.90M$20.96M$30.58M
Weighted-average diluted sharesshares 15.01Mshares 11.25Mshares 4.49MUnavailableshares 21.20MUnavailableUnavailable
Pretax income-$29.56M-$13.70MUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$1.00K$1.00KUnavailableUnavailableUnavailable
Diluted EPS$-1.97$-1.22$-7.66$-111.16$-1.69UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.89M$9.73M$22.22M$5.84M$17.04M$8.87M$6.92M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CalciMedica, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$11.52M$7.94M$5.53M$1.33M$13.36M$33.42M$15.87M
Total assets$13.59M$19.79M$12.18M$3.35M$69.09M$101.79M$40.66M
Current assets$13.53M$19.66M$11.60M$1.73M$67.08M$99.24M$36.27M
Total liabilities$20.23M$5.38M$4.03M$12.58M$4.06M$7.01M$12.25M
Current liabilities$3.78M$3.68M$4.03M$4.78M$4.06M$7.00M$12.25M
Total equity incl. NCI-$6.64M$14.41M$8.16M-$71.30M-$63.99M$94.79M-$102.95M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$131.36M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.16M$2.00M$1.42M$2.87M$527.00K$2.51M$4.64M

Cash flow

CalciMedica, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$21.18M-$21.15M-$25.73M-$11.76M-$31.50M-$32.06M-$31.22M
Capital expenditures$28.00K$8.00K$78.00K$4.00K$488.00K$1.02M$605.00K
Investing cash flow$9.55M-$4.42M$8.88M-$4.00K$10.75M-$42.56M-$20.62M
Financing cash flow$15.21M$27.97M$20.90M$8.48M$695.00K$92.17M$54.87M
Net change in cash$3.58M$2.40M$4.05M-$3.28M-$20.05M$17.55M$3.04M
Stock-based compensation$2.97M$2.31M$12.04M$1.81M$5.38M$1.79M$738.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$58.00K$52.00KUnavailableUnavailableUnavailable

Derived

CalciMedica, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$21.21M-$21.15M-$25.81M-$11.76M-$31.99M-$33.09M-$31.82M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio3.58x5.34x2.88x0.36x16.53x14.18x2.96x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CALC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2022-12-31

Difference 62071000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2021-12-31

Difference 129010000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.